American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer

Catherine H. Van Poznak, Sarah Temin, Gary C. Yee, Nora A. Janjan, William E. Barlow, J. Sybil Biermann, Linda D. Bosserman, Cindy Geoghegan, Bruce E. Hillner, Richard L. Theriault, Dan S. Zuckerman, Jamie H. Von Roenn

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

Purpose: To update the recommendations on the role of bone-modifying agents in the prevention and treatment of skeletal-related events (SREs) for patients with metastatic breast cancer with bone metastases. Methods: A literature search using MEDLINE and the Cochrane Collaboration Library identified relevant studies published between January 2003 and November 2010. The primary outcomes of interest were SREs and time to SRE. Secondary outcomes included adverse events and pain. An Update Committee reviewed the literature and re-evaluated previous recommendations. Results: Recommendations were modified to include a new agent. A recommendation regarding osteonecrosis of the jaw was added. Recommendations: Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence to demonstrate greater efficacy of one bone-modifying agent over another. In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change in dosage, infusion time, or interval of bisphosphonate administration is required. Serum creatinine should be monitored before each dose. All patients should receive a dental examination and appropriate preventive dentistry before bone-modifying agent therapy and maintain optimal oral health. Current standards of care for cancer bone pain management should be applied at the onset of pain, in concert with the initiation of bonemodifying agent therapy. The use of biochemical markers to monitor bone-modifying agent use is not recommended.

Original languageEnglish (US)
Pages (from-to)1221-1227
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number9
DOIs
StatePublished - Mar 20 2011

Fingerprint

Practice Guidelines
Breast Neoplasms
Bone and Bones
Bone Neoplasms
pamidronate
zoledronic acid
Creatinine
Preventive Dentistry
Neoplasm Metastasis
Pain
Osteonecrosis
Oral Health
Diphosphonates
Pain Management
Therapeutics
Standard of Care
Jaw
Serum
MEDLINE
Libraries

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. / Van Poznak, Catherine H.; Temin, Sarah; Yee, Gary C.; Janjan, Nora A.; Barlow, William E.; Biermann, J. Sybil; Bosserman, Linda D.; Geoghegan, Cindy; Hillner, Bruce E.; Theriault, Richard L.; Zuckerman, Dan S.; Von Roenn, Jamie H.

In: Journal of Clinical Oncology, Vol. 29, No. 9, 20.03.2011, p. 1221-1227.

Research output: Contribution to journalArticle

Van Poznak, CH, Temin, S, Yee, GC, Janjan, NA, Barlow, WE, Biermann, JS, Bosserman, LD, Geoghegan, C, Hillner, BE, Theriault, RL, Zuckerman, DS & Von Roenn, JH 2011, 'American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer', Journal of Clinical Oncology, vol. 29, no. 9, pp. 1221-1227. https://doi.org/10.1200/JCO.2010.32.5209
Van Poznak, Catherine H. ; Temin, Sarah ; Yee, Gary C. ; Janjan, Nora A. ; Barlow, William E. ; Biermann, J. Sybil ; Bosserman, Linda D. ; Geoghegan, Cindy ; Hillner, Bruce E. ; Theriault, Richard L. ; Zuckerman, Dan S. ; Von Roenn, Jamie H. / American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 9. pp. 1221-1227.
@article{aae4f3b04dea41c3a95ff62dcdb830c6,
title = "American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer",
abstract = "Purpose: To update the recommendations on the role of bone-modifying agents in the prevention and treatment of skeletal-related events (SREs) for patients with metastatic breast cancer with bone metastases. Methods: A literature search using MEDLINE and the Cochrane Collaboration Library identified relevant studies published between January 2003 and November 2010. The primary outcomes of interest were SREs and time to SRE. Secondary outcomes included adverse events and pain. An Update Committee reviewed the literature and re-evaluated previous recommendations. Results: Recommendations were modified to include a new agent. A recommendation regarding osteonecrosis of the jaw was added. Recommendations: Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence to demonstrate greater efficacy of one bone-modifying agent over another. In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change in dosage, infusion time, or interval of bisphosphonate administration is required. Serum creatinine should be monitored before each dose. All patients should receive a dental examination and appropriate preventive dentistry before bone-modifying agent therapy and maintain optimal oral health. Current standards of care for cancer bone pain management should be applied at the onset of pain, in concert with the initiation of bonemodifying agent therapy. The use of biochemical markers to monitor bone-modifying agent use is not recommended.",
author = "{Van Poznak}, {Catherine H.} and Sarah Temin and Yee, {Gary C.} and Janjan, {Nora A.} and Barlow, {William E.} and Biermann, {J. Sybil} and Bosserman, {Linda D.} and Cindy Geoghegan and Hillner, {Bruce E.} and Theriault, {Richard L.} and Zuckerman, {Dan S.} and {Von Roenn}, {Jamie H.}",
year = "2011",
month = "3",
day = "20",
doi = "10.1200/JCO.2010.32.5209",
language = "English (US)",
volume = "29",
pages = "1221--1227",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer

AU - Van Poznak, Catherine H.

AU - Temin, Sarah

AU - Yee, Gary C.

AU - Janjan, Nora A.

AU - Barlow, William E.

AU - Biermann, J. Sybil

AU - Bosserman, Linda D.

AU - Geoghegan, Cindy

AU - Hillner, Bruce E.

AU - Theriault, Richard L.

AU - Zuckerman, Dan S.

AU - Von Roenn, Jamie H.

PY - 2011/3/20

Y1 - 2011/3/20

N2 - Purpose: To update the recommendations on the role of bone-modifying agents in the prevention and treatment of skeletal-related events (SREs) for patients with metastatic breast cancer with bone metastases. Methods: A literature search using MEDLINE and the Cochrane Collaboration Library identified relevant studies published between January 2003 and November 2010. The primary outcomes of interest were SREs and time to SRE. Secondary outcomes included adverse events and pain. An Update Committee reviewed the literature and re-evaluated previous recommendations. Results: Recommendations were modified to include a new agent. A recommendation regarding osteonecrosis of the jaw was added. Recommendations: Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence to demonstrate greater efficacy of one bone-modifying agent over another. In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change in dosage, infusion time, or interval of bisphosphonate administration is required. Serum creatinine should be monitored before each dose. All patients should receive a dental examination and appropriate preventive dentistry before bone-modifying agent therapy and maintain optimal oral health. Current standards of care for cancer bone pain management should be applied at the onset of pain, in concert with the initiation of bonemodifying agent therapy. The use of biochemical markers to monitor bone-modifying agent use is not recommended.

AB - Purpose: To update the recommendations on the role of bone-modifying agents in the prevention and treatment of skeletal-related events (SREs) for patients with metastatic breast cancer with bone metastases. Methods: A literature search using MEDLINE and the Cochrane Collaboration Library identified relevant studies published between January 2003 and November 2010. The primary outcomes of interest were SREs and time to SRE. Secondary outcomes included adverse events and pain. An Update Committee reviewed the literature and re-evaluated previous recommendations. Results: Recommendations were modified to include a new agent. A recommendation regarding osteonecrosis of the jaw was added. Recommendations: Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence to demonstrate greater efficacy of one bone-modifying agent over another. In patients with a calculated serum creatinine clearance of more than 60 mg/min, no change in dosage, infusion time, or interval of bisphosphonate administration is required. Serum creatinine should be monitored before each dose. All patients should receive a dental examination and appropriate preventive dentistry before bone-modifying agent therapy and maintain optimal oral health. Current standards of care for cancer bone pain management should be applied at the onset of pain, in concert with the initiation of bonemodifying agent therapy. The use of biochemical markers to monitor bone-modifying agent use is not recommended.

UR - http://www.scopus.com/inward/record.url?scp=79952743744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952743744&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.32.5209

DO - 10.1200/JCO.2010.32.5209

M3 - Article

C2 - 21343561

AN - SCOPUS:79952743744

VL - 29

SP - 1221

EP - 1227

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -